SFI
STOK icon

Susquehanna Fundamental Investments’s Stoke Therapeutics STOK Stock Holding History

Susquehanna Fundamental Investments’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-7,682
Closed -$298K – 1776
2021
Q1 		$298K Sell
7,682
-1,308
-15% -$74.5K 0.01% 1293
2020
Q4 		$557K Buy
+8,990
New +$412K 0.01% 1062

Other funds holding STOK

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Susquehanna Fundamental Investments's STOK Position: Q2 2021 in Review

Susquehanna Fundamental Investments sold out of Stoke Therapeutics (STOK) in Q2 2021, closing a stake of 7,682 shares — an estimated $298K sold.

Susquehanna Fundamental Investments first reported a position in STOK in Q4 2020 and held it in 2 quarters. The position peaked at $557K in Q4 2020. 97 funds tracked by Wall St. Rank hold STOK as of Q2 2021.

  • Susquehanna Fundamental Investments reported no remaining Stoke Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 7,682 Stoke Therapeutics shares in Q2 2021, an estimated $298K.
  • Susquehanna Fundamental Investments first reported a position in Stoke Therapeutics in Q4 2020 and held it in 2 quarters.
  • Susquehanna Fundamental Investments's Stoke Therapeutics position peaked at $557K in Q4 2020.
  • 97 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2021, filed 11 Aug 2021.